Ocular pharmacokinetics of verapamil in rabbits

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 357, Issue 3, 1998, Pages 331-335

  Ettl, Armin ^a,b   Hofmann, Ute ^c   Daxer, Albert ^b   Dietrich, Hermann ^b   Schmid, Eduard ^b   Eichelbaum, Michel ^c  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

Cataract; Eye; Glaucoma; Pharmacokinetics; Verapamil

Indexed keywords

VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS HUMOR; AQUEOUS SOLUTION; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR EFFECT; CATARACT; CONTROLLED STUDY; DRUG EFFECT; HALF LIFE TIME; INTRAOCULAR HYPERTENSION; MASS SPECTROMETRY; NONHUMAN; RABBIT; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; AQUEOUS HUMOR; INJECTIONS, SUBCUTANEOUS; MALE; RABBITS; VASODILATOR AGENTS; VERAPAMIL;

EID: 0031915228     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00005175     Document Type: Article

References (32)

1. Abelson MB, Smith LM (1988) Sustained reduction of intraocular pressure in humans with the calcium channel blocker verapamil. Am J Ophthalmol 105:155-159
2. Anderson P, Bondesson U, Sylven C, Aström H (1982) Plasma concentration - response relationship of verapamil in the treatment of angina pectoris. J Cardiovasc Pharmacol 4: 609-614
3. Bartels SP (1989) Aqueous humor formation: fluid production by a sodium pump. In: Ritch R, Shields MB, Krupin T (eds) The glaucomas. Mosby, St, Louis, pp 199-218
4. Beaton MA, Erickson KA, Schroeder A (1994) Effects of topical verapamil on intraocular pressure, aqueous flow and outflow facility in humans. Invest Ophthalmol Vis Sci 35 [Suppl]: 1483
5. Becher I (1972) Untersuchungen über den Einfluß einer peroralen Verapamil-Applikation auf die Entwicklung der Galactosekatarakt bei Ratten. Thesis, University of Bonn
6. Eichelbaum M, Mikus G, Vogelgesang B (1984): Pharmacokinetics of (+)-, (_)-. (±)-verapamil after intravenous administration. Br J Clin Pharmacol 17: 453-458
7. Ettl A, Schmid E, Daxer A (1994) Prevention of cataract in streptozotocin diabetic rats by verapamil eye drops. Doc Ophthalmol 85: 324
8. Feke GT, Netland PA, Konno S, Goger DG, Fujio N (1995) Topical verapamil lowers intraocular pressure and increases optic nerve head capillary blood speed in normal subjects. Invest Ophthalmol Vis Sci 36 [Suppl]: 823
9. Fleckenstein A (1984) Prevention by verapamil of arterial calcium overload and concomitant lenticular calcification causing cataracts in alloxan-diabetic rats. In: Fleckenstein A (ed) Calciumantagonism in heart and smooth muscle. John Wiley, New York, pp 280-285
10. Gardner SK (1987) Ocular drug penetration and pharmacokinetic principles.In: Lamberts DW, Potter DE (eds) Clinical ophthalmic pharmacology. Little, Boston, pp 1-53
11. Giacomini JC, Nelson WL, Theodore L, Wong FM, Rood D, Giacomini KM (1985) The pharmacokinetics and pharmacodynamics of d- and dl-verapamil in rabbits. J Cardiovasc Pharmacol 7: 469-475
12. Gilman AG, Goodman LS, Rall TW, Murad F (1985) The pharmacological basis of therapeutics. Macmillan, New York, p 1712
13. Goyal JK, Khilnany G, Sharma DP, Singh J (1989): The hypotensive effect of verapamil eye drops on ocular hypertension. Ind J Ophthalmol 37: 176
14. Greiner JV. Glonek T (1988) Effects of the slow calcium-channel blocker verapamil on phosphatic metabolism of crystalline lens. Exp Eye Res 46: 139-148
15. Gross A, Borstel B, Eichelbaum M (1990) Determination of Gallopamil in serum by gas chromatographv-mass spectrometry. J Chromatogr Biomed Appl 525: 183-192
16. Heinzel G, Woloszak R, Thomann P (1993) Top Fit: pharmacokinetic and pharmacodynamic data analysis for the PC. G Fischer. Stuttgart
17. Hockwin O, Dragomirescu V, Laser H, Ohrloff C, Kozamanoglu K. Kremer F (1984) Evaluation of the ocular safety of verapamil. Scheimpflug photography with densitometric image analysis of lens transparency in patients with hypertrophie cardiomyopathy subjected to long-term therapy with high doses of verapamil. Ophthalmic Res 16: 264-275
18. Latour E, Chambaudy A, Calmette C, Coquelet C (1995) Compared effects of DL,- and L-verapamil on intraocular pressure (IOP) and corneal sensitivity. Invest Ophthalmol Vis Sci 36 [Suppl]: 718
19. Lee JH, Kim SY, Yang JE, Choe YJ, Hong YJ (1994) Topical effect of verapamil on outflow in rabbits. Invest Ophthalmol Vis Sei 35 [Suppl]: 2053
20. Maurice DM, Mishima S (1984) Ocular pharmacokinetics. In: Sears ML (ed) Pharmakology of the eye. Springer, New York, pp 19-116
21. McTavish D, Sorkin EM (1989) Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension. Drugs 38: 19-76
22. Mooshian ML, Leonardi LM, Schooley GL, Erickson K, Greiner JV (1993) One drop study to evaluate safety and efficacy of an ophthalmic calcium channel blocker, verapamil, in subjects with elevated intraocular pressure. Invest Ophthalmol Vis Sci 34 [Suppl]: 924
23. Morris SM, Devamanoharan PS, Varma SD (1995) Inhibition of polyol formation in rat lens by verapamil. Invest Ophthalmol Vis Sci 36 [Suppl]: 801
24. Müller P, Hockwin O, Ohrloff C (1985) Comparison of aldose reductase inhibitors by determination of IC50 with bovine and rat lens extracts. Ophthalmic Res 17: 115-119
25. Pierce GN, Kroeger EA, Lockwood MK, Kutryk MJB. Eckhert CD, Dhalla NS(1989) Cataract formation is prevented by administration of verapamil to diabetic rats. Endocrinology 125: 730-735
26. Poyer JF, Gabelt B, Kaufman PL (1992) The effect of topical PGF2 alpha on uveoscleral outflow and outflow facility in the rabbit eye. Exp Eye Res 54: 277-283
27. Rattke W, Glässer D (1978) Effects of verapamil on bovine lens epithelium in primary culture. Ophthalmic Res 10: 162-167
28. Schmid E, Ettl A (1995) Image analysis of lenses from untreated and treated diabetic rats. Inv Ophthalmol Vis Sci 36 [Suppl]: 266
29. Schomerus M, Spiegelhalder B, Stieren B, Eichelbaum M (1976) Physiological disposition of verapamil in man. Cardiovasc Res 10:605-612
30. Schroeder A, Erickson KA (1993) Verapamil increases facility of outflow in the human eye in vitro. Invest Ophthalmol Vis Sci 34 [Suppl]: 924
31. Urtti A, Salminen L (1993) Minimizing systemic absorption of topically administered ophthalmic drugs. Surv Ophthalmol 378: 435-456
32. Zhang X, Schroeder A, Erickson K (1994) Influence of verapamil and epinephrine on outflow facility and cyclic AMP in the human eye. Invest Ophthalmol Vis Sci 35 [Suppl]: 2053